CA2400497A1 - Procedes et compositions permettant de produire de l'angiostatine - Google Patents

Procedes et compositions permettant de produire de l'angiostatine Download PDF

Info

Publication number
CA2400497A1
CA2400497A1 CA002400497A CA2400497A CA2400497A1 CA 2400497 A1 CA2400497 A1 CA 2400497A1 CA 002400497 A CA002400497 A CA 002400497A CA 2400497 A CA2400497 A CA 2400497A CA 2400497 A1 CA2400497 A1 CA 2400497A1
Authority
CA
Canada
Prior art keywords
angiostatin
pro
gly
thr
plasminogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002400497A
Other languages
English (en)
Inventor
Gerald Soff
Stephen T. Gately
Przemyslaw Twardowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Northwestern University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2400497A1 publication Critical patent/CA2400497A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A61K38/166—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/968—Plasmin, i.e. fibrinolysin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Food Science & Technology (AREA)

Abstract

L'invention concerne des procédés permettant de produire de l'angiostatine in vitro, qui consistent à mettre en contact du plasminogène avec un activateur de plasminogène et un donneur sulfhydryle ou à mettre en contact une plasmine avec un donneur sulfhydryle. La présente invention concerne aussi une méthode de traitement de maladies angiogéniques qui consiste à administrer à un animal souffrant d'une telle maladie un donneur sulfhydryle et, éventuellement, un activateur de plasminogène, ou une combinaison des deux. La présente invention concerne également une composition destinée à produire de l'angiostatine, qui comporte un donneur sulfhydryle et un activateur de plasmonigène, et un récipient contenant un donneur sulfhydryle et/ou un activateur de plasminogène, ledit récipient portant une étiquette sur laquelle figurent des instructions concernant l'administration du donneur sulfhydryle et/ou de l'activateur de plasminogène à un animal souffrant d'une maladie angiogénique. La présente invention concerne encore des fragments de plasminogène dont l'acide aminé N-terminal est le même que celui de la plasmine et dont l'acide aminé C-terminal est situé dans le kringle 5, et qui inhibent l'angiogenèse, des anticorps qui se lient sélectivement à ces fragments, des procédés et des kits destinés à utiliser ces anticorps, des procédés et des substances permettant d'obtenir lesdits fragments par des techniques de recombinaison d'ADN, et une méthode de traitement des maladies angiogéniques qui consiste à administrer une quantité efficace de l'un des fragments. La présente invention concerne enfin une méthode de traitement d'une maladie angiogénique qui consiste à administrer un transgène codant pour l'un des fragments.
CA002400497A 2000-02-08 2001-02-08 Procedes et compositions permettant de produire de l'angiostatine Abandoned CA2400497A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50039700A 2000-02-08 2000-02-08
US09/500,397 2000-02-08
PCT/US2001/004021 WO2001058921A2 (fr) 2000-02-08 2001-02-08 Procedes et compositions permettant de produire de l'angiostatine

Publications (1)

Publication Number Publication Date
CA2400497A1 true CA2400497A1 (fr) 2001-08-16

Family

ID=23989238

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002400497A Abandoned CA2400497A1 (fr) 2000-02-08 2001-02-08 Procedes et compositions permettant de produire de l'angiostatine

Country Status (5)

Country Link
EP (1) EP1263452A4 (fr)
JP (1) JP2004508006A (fr)
AU (1) AU2001234926A1 (fr)
CA (1) CA2400497A1 (fr)
WO (1) WO2001058921A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012000475A (es) 2009-07-10 2012-03-26 Thrombogenics Nv Variantes de plasminogeno y plasmina.
EP2661493B1 (fr) 2011-01-05 2016-03-30 ThromboGenics N.V. Variantes de plasminogène et de plasmine
CN103764163A (zh) 2011-08-12 2014-04-30 斯路姆基因公司 纤溶酶原和纤溶酶变体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988003030A1 (fr) * 1986-10-31 1988-05-05 Moscatelli David A PROCEDE D'INDUCTION DE LA PRODUCTION ENDOGENE DE L'ACTIVATEUR DE PLASMINOGENE TISSULAIRE (tPA)
NZ230808A (en) * 1988-10-24 1993-04-28 Squibb & Sons Inc Pharmaceutical compositions and combinations containing an angiotensin-converting enzyme inhibitor and a thrombolytic agent
US5801012A (en) * 1996-09-17 1998-09-01 Northwestern University Methods and compositions for generating angiostatin

Also Published As

Publication number Publication date
WO2001058921A3 (fr) 2002-02-14
WO2001058921A9 (fr) 2002-03-14
JP2004508006A (ja) 2004-03-18
WO2001058921A2 (fr) 2001-08-16
AU2001234926A1 (en) 2001-08-20
EP1263452A2 (fr) 2002-12-11
EP1263452A4 (fr) 2006-12-20

Similar Documents

Publication Publication Date Title
US6576609B1 (en) Methods and compositions for generating angiostatin
US5801146A (en) Compound and method for inhibiting angiogenesis
KR100336452B1 (ko) 앤지오스타틴및맥관형성억제를위한이의사용방법
JP4426650B2 (ja) 新規な抗血管形成ペプチド、それをコードするポリヌクレオチド、および血管形成を阻害する方法
US6521439B2 (en) Nucleic acids encoding plasminogen fragments
EP0824546B1 (fr) Fragments d'angiostatine et procedes d'utilisation
WO1998054217A1 (fr) Fragments d'angiostatine et leur procede d'utilisation
JP2002510209A (ja) インビボで血管形成を調節することができるプラスミノーゲンのクリングルドメイン１−５
US20060099671A1 (en) Methods and compositions for generating angiostatin
CA2400497A1 (fr) Procedes et compositions permettant de produire de l'angiostatine
JP2002516261A (ja) セリンプロテアーゼを利用して内皮細胞増殖を阻害し血管新生を調節するための組成物と方法
JP4666767B2 (ja) プラスミノーゲンの脱グリコシル化クリングル１〜５領域フラグメント及びこれらの使用方法
WO2000049871A1 (fr) Proteine kringle antiangiogenique et ses mutants
JP2002535372A (ja) プラスミノーゲンクリングル４領域フラグメントおよび利用法
US7157556B1 (en) Deglycosylated kringle 1-3 region fragments of plasminogen and methods of use
MXPA99011041A (en) Angiostatin fragments and method of use
AU7704998A (en) Angiostatin fragments and method of use
MXPA98009612A (en) Antiangiogenic drug to treat cancer, arthritis and retinopathy

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued
FZDE Discontinued

Effective date: 20100208